CoChat

BET bromodomain inhibitors: a patent review

Garnier, Jean-Marc, Sharp, Phillip P, Burns, Christopher J · 2014 · Expert Opinion on Therapeutic Patents
Cited by 119

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The bromodomain (BRD) and extra-C terminal domain (BET) protein family consists of four members (BRD2, BRD3, BRD4 and BRDT). These "epigenetic readers" bind to acetyllysine (KAc) residues on the tails of histones H3 and H4, and regulate chromatin structure and gene expression. There is increasing evidence of their role in human disease, and recently a number of small-molecule inhibitors have been reported. There is increasing interest in the inhibition of BET proteins for a variety of therapeutic applications that have resulted in considerable patent activity from academia and biotechnology and pharmaceutical companies. AREAS COVERED: Data supporting the use of BET inhibitors in treating disease are outlined, and the current patent literature is discussed. The survey is focused on patents claiming compounds as BET inhibitors and additional patents covering compounds now reported as BET inhibitors have been included. EXPERT OPINION: There is now compelling preclinical data demonstrating BET inhibition as a strategy to target processes known to be involved in disease development and progression with clinical trials of two bona fide BET inhibitors now underway. Patent activity in this area is increasing with initial activity focused on variations to reported BET inhibitors and more recent patents disclosing novel chemotypes as BET inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543776.2014.859244

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Selective inhibition of BET bromodomains

    Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 7×

    “JQ1 (1) was obtained after simple modification of BRD4 inhibitors patented by Mitsubishi Pharmaceuticals [27], whereas I-BET762 (2) was derived from medicinal chemistry optimization of a hit derived from a phenotypic screen to identify small molecules able to enhance ApoA1 expression [28,61].”
    BackgroundMethodInfluential
  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

    Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 2×

    “The data presented in support of these claims are focused on JQ1 (1) and have subsequently been published in the peerreviewed literature [33].”
    Background
  • Structure and ligand of a histone acetyltransferase bromodomain

    Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732 · cited 1×

    “The first BRD structure was determined by nuclear magnetic resonance spectroscopy in 1999 [10] and since then, the solution and/or crystal”
    Method
  • Reflecting on 25 years with MYC

    Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×

    “For example, the data discussed earlier, which indicate that BET inhibitors are effective against MYC-expressing cells, are extremely exciting: MYC is deregulated in >50% of cancers and is notoriously difficult to target directly [108].”
  • Suppression of inflammation by a synthetic histone mimic

    Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563 · cited 5×

    “JQ1 (1) was obtained after simple modification of BRD4 inhibitors patented by Mitsubishi Pharmaceuticals [27], whereas I-BET762 (2) was derived from medicinal chemistry optimization of a hit derived from a phenotypic screen to identify small molecules able to enhance ApoA1 expression [28,61].”
    BackgroundMethodResultInfluential
  • Privileged scaffolds for library design and drug discovery

    Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.018 · Cited by 1,509 · cited 1×

    “Last, given the extensive work in the pharmaceutical industry over the past 50 years in benzodiazepine chemistry, and its recognition as a privileged scaffold in medicinal chemistry [107], one wonders firstly whether novel chemical matter can be identified and secondly whether these compounds may have other, as yet un…”
    Background
  • Epigenetic protein families: a new frontier for drug discovery

    Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · cited 1×

    “The clinical utility of, and experience with, HDAC inhibitors and DNAmethyl transferase inhibitors in the treatment of specific cancers has given impetus to the discovery of new drugs selectively targeting other epigenetic processes for cancer and other diseases [101].”
    Background
  • Growth and Early Postimplantation Defects in Mice Deficient for the Bromodomain-Containing Protein Brd4

    Houzelstein, D., Bullock, S. L., Lynch, D. E., Grigorieva, E. F., Wilson, V. A., & Beddington, R. S. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3794-3802.2002 · Cited by 318 · cited 1×

    “Despite early attempts over a decade ago [103], at present only two such models have been published [53,50].”
    Background
  • Place your BETs: the therapeutic potential of bromodomains

    Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197 · cited 2×

    “A number of excellent articles have been recently published on BRD biology, structure and the therapeutic potential of specific BRD inhibition, and the interested reader is directed to these for detailed information [1-6]: herein this article seeks to summarizes the most relevant and salient features of BRDs.”
    Background
  • Brd2 disruption in mice causes severe obesity without Type 2 diabetes

    Wang, F., Liu, H., Blanton, W. P., Belkina, A., Lebrasseur, N. K., & Denis, G. V. (2010) · Biochemical Journal · doi:10.1042/bj20090928 · Cited by 185 · cited 4×

    “The role of BET family proteins in adipogenesis has, however, previously been reported [50,51].”
    BackgroundInfluential

Cited by

See all 119

Metadata

Authors
Garnier, J.-M., Sharp, P. P., & Burns, C. J.
Venue
Expert Opinion on Therapeutic Patents
Published
2013-11-22
Volume
24
Issue
2
Pages
185-199
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W2056181477
Cited by
119
References
10
FWCI
6.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.